MRI-guided bladder preservation for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new treatment approach using MRI to guide bladder preservation for patients with muscle-invasive bladder cancer. The goal is to treat the cancer with chemotherapy and radiation instead of removing the bladder, potentially allowing you to keep your bladder while fighting the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have muscle-invasive bladder cancer (stage T2 or T3) that has not spread beyond the bladder (N0, M0) and is a single tumor (unifocal).
- You must have had a maximal TURBT (a surgical procedure to remove the tumor through the urethra) and be able to handle concurrent chemotherapy and radiation therapy.
- Your overall health must be good (Karnofsky performance status >70) and your blood tests must meet certain levels (e.g., white blood cells ≥3500, platelets ≥135000, hemoglobin ≥10, kidney function within limits).
- You cannot have squamous cell carcinoma or adenocarcinoma bladder cancer (these are different types of bladder cancer that are not eligible).
- You must not have had prior radiation therapy to the area where the cancer is, and you must be able to have an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced MRI scanning to guide treatment decisions for muscle invasive bladder cancer. It aims to improve outcomes by personalizing therapy based on detailed imaging.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
This study collects information from people with muscle-invasive bladder cancer who have had chemotherapy or immunotherapy and then decided not to have their bladder removed. It looks at different ways to preserve the bladder and how well those approaches work.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This study uses a special MRI scan (mpMRI) to figure out how far suspected muscle-invasive bladder cancer has spread, using a new local staging approach. If the results are accurate, it may help doctors plan the most appropriate curative treatment sooner.
This study watches people with muscle-invasive bladder cancer who choose to keep their bladder after receiving neoadjuvant therapy (treatment before the main treatment). It aims to see how well bladder-preserving treatments like chemoradiation work over time.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.